Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT02123199
NCT02123199CompletedNot Applicable

Prospective Observational Study of the Impact of Indacaterol (Onbrez®) on the Individual Lives and Health Status of Patients With COPD

Novartis Pharmaceuticals1 site in 1 country103 target enrollmentStarted: April 2012Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions
Interventions
Drugs

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
103
Locations
1
Primary Endpoint
Change in COPD assessment Test (CAT Score) at 6-8 weeks after the initiation of indacaterol
Study OverviewStudy DesignEligibility CriteriaArms & InterventionsOutcomesInvestigatorsSitesRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

A prospective observational multi centre research study in GP practices clustered within up to 10 UK Primary care trusts.

Study Design

Study Type
Observational
Observational Model
Cohort
Time Perspective
Prospective

Eligibility Criteria

Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Patients with active diagnosis of COPD, confirmed by spirometry documented in medical notes

Exclusion Criteria

  • •Patients who are currently receiving other maintenance therapy (except LAMA) for COPD.
  • •Patients previously prescribed Indacaterol.

Arms & Interventions

Indacaterol/QAB149

Patients treated with Indacaterol for COPD prior to enrollment in study

Intervention: Indacaterol (Onbrez®) /QAB149 (Drug)

Outcomes

Primary Outcomes

Change in COPD assessment Test (CAT Score) at 6-8 weeks after the initiation of indacaterol

Time Frame: 6-8 weeks

Secondary Outcomes

  • Physician Global Evaluation of Treatment effectiveness (GETE) at 6-8 weeks and 6 months.(6-8 weeks and 6 months)
  • Patient Global Evaluation of Treatment effectiveness (GETE) at 6 months(6 months)
  • Change in COPD Assessment test (CAT) score at 6 months after the initiation of indacaterol(6 months)
  • Impact of indacaterol on patients' lies at 6 - 8 weeks after the initiation of indacaterol.(6-8 weeks)

Investigators

Sponsor Class
Industry
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials

Terminated
Not Applicable
Retrospective Study on Clinical Performance and Safety Profile of MJ-Flex Elastic NailFractures, Bone
NCT06412913Orthofix s.r.l.6
Terminated
Not Applicable
Retrospective Study on Clinical Performance and Safety Profile of Agile NailFractures, BoneImpending FractureBone Deformity
NCT06412939Orthofix s.r.l.20
Completed
Not Applicable
An Observational Study of MabThera in Participants With Severe Active Rheumatoid ArthritisRheumatoid Arthritis
NCT01613027Hoffmann-La Roche135
Recruiting
Not Applicable
Study to Evaluate the Performance and Safety of ATF Implants and Lapé Médical Devices Implanted During Hip ArthroplastyArthroplasty, Hip, Replacement
NCT05044767ATF Implants4,500
Completed
Not Applicable
Multicenter prospective observational study on the effectiveness of hypofractionated palliative radiotherapy for advanced head and neck squamous cell carcinoma (JROSG 18-2)Advanced head and neck squamous cell carcinoma
JPRN-UMIN000039971Japanese Radiation Oncology Study Group (JROSG)50
Study of the Impact of Indacaterol... | Clinical Trial